

Supplemental Table S1: Vaccination status of the 133 cancer patients of this study before acquiring a SARS-CoV-2 infection.

COVID-19 vaccination status		
Vaccinated patients (<i>n</i> and %)	49/133	37%
Data of the vaccinated patients	<i>n</i> = 49	100%
Type of first vaccination		
Vaxzevria AZD1222	4	8%
Comirnaty BNT162b2	36	72%
Spikevax mRNA-1273	2	4%
Johnson and Johnson Ad26.COV2.S	2	4%
Missing	5	5%
Type of second vaccination	48/49	
Vaxzevria AZD1222	1	2%
Comirnaty BNT162b2 or Spikevax mRNA-1273	3	6%
Comirnaty BNT162b2	38	79%
Missing	6	13%
Summary of COVID-19 vaccines among double vaccinated patients	48/49	98%
Vector based vaccine followed by mRNA	4	8%
Vector based only	1	2%
mRNA based only	37	77%
Missing	6	13%
Third vaccination (mRNA based only)	17/49	35%
Median time from vaccination until SARS-CoV-19 infection in days (range)	129	2-268